Download PDF
Aktuelle Neurologie 2011; 38: S34-S38
DOI: 10.1055/s-0030-1265982
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Wirkung von Apomorphin auf nicht motorische Symptome bei Morbus Parkinson

Effect of Apomorphine on Non-Motor Symptoms in Parkinson's DiseaseH.  Honig1 , P.  Odin1 , 2 , K.  R.  Chaudhuri3
  • 1Abt. Neurologie, Klinikum-Bremerhaven, Bremerhaven, Deutschland
  • 2Abt. Neurologie, Universitätskrankenhaus, Lund, Schweden
  • 3NPF Centre of Excellence, Dept of Neurology, King's College, London, UK
Further Information

Publication History

Publication Date:
22 February 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nicht motorische Symptome können bereits vor den motorischen Symptomen einer Parkinsonerkrankung auftreten. Neben Wirkungsfluktuationen und Dyskinesien stellen nicht motorische Symptome ein Hauptproblem in der Behandlung der fortgeschrittenen Parkinsonerkrankung dar. Sie sind von wesentlicher Bedeutung für die Lebensqualität. Es gibt Hinweise darauf, dass eine kontinuierliche dopaminerge Stimulation Depression, Schlaf und autonome Störungen verbessern kann. Medikamentenpumpen mit Apomorphin subkutan oder Duodopa (L-Dopa / Carbidopagel) intraduodenal haben sich zur Behandlung von motorischen Wirkungsfluktuationen und Dyskinesien etabliert. Im Bereich der nicht motorischen Symptome liegen bisher nur wenige Studien mit kleinen Fallzahlen vor.

Abstract

In Parkinson's disease non-motor symptoms can appear even before the motor symptoms. Additionally to motor fluctuations and dyskinesias, the non-motor symptoms constitute one of the main problems when treating Parkinson's disease. They are also of high relevance for the quality of life. There are indications that a continuous dopaminergic stimulation can improve symptoms such as depression, sleep as well as autonomic disturbances. Treatment with apomorphine infusion subcutaneously or Duodopa (L-dopa / carbidopa) intraduodenally with portable pump systems are well-established regarding management of motor fluctuations and dyskinesias. Regarding effects on non-motor symptoms there are so far only a few studies with limited number of cases available.

Schlüsselwörter

Parkinson - Pumpe - Apomorphin - Infusion - Non-motor

Keywords

Parkinson - pump - apomorphine - infusion - non-motor

Literatur

  • 1 Chaudhuri K R, Healy D, Schapira A HV. The non motor symptoms of Parkinson's disease. Diagnosis and management.  Lancet Neurol. 2006;  5 235-245
    CrossrefPubMedGoogle Scholar
  • 2 Naidu Y, Chaudhuri K R. Early Parkinson's disease and non motor issues.  J Neurol. 2008;  255 33-38
    CrossrefPubMedGoogle Scholar
  • 3 Tolosa E et al. Diagnosis and the premotor phase of Parkinson disease.  Neurology. 2009;  72 (S 02) S12-S20
    CrossrefPubMedGoogle Scholar
  • 4 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson's disease and Related Disorders. Park Related Disorders P0II: 161.. Dresden; October/2008
    Google Scholar
  • 5 Chaudhuri K R, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease.  Eur J Neurol. 2008;  15 2-7
    CrossrefPubMedGoogle Scholar
  • 6 Chaudhuri K R, Martinez-Martin P, Schapira A HV et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study.  Mov Disord. 2006;  21 916-923
    CrossrefPubMedGoogle Scholar
  • 7 Politis M, Piccini P, Pavese N et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C raclopride study.  Exp Neurol. 2008;  214 112-116
    CrossrefPubMedGoogle Scholar
  • 8 Storch A, Ebersbach G, Fuchs G et al. Depression in Parkinson's disease. Part 1: Epidemiology, signs and symptoms, pathophysiology and diagnosis.  Fortschr Neurol Psychiatr. 2008;  76 715-724
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Remy P, Doder M, Lees A et al. Depression in Parkinson's disease. Loss of dopamine and noradrenaline innervations in the limbic system.  Brain. 2005;  128 1314-1322
    CrossrefPubMedGoogle Scholar
  • 10 Corrigan M H, Denahan A Q, Wright C E et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.  Depress Anxiety. 2000;  11 58-65
    CrossrefPubMedGoogle Scholar
  • 11 Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.  Eur J Neurol. 2003;  10 399-406
    CrossrefPubMedGoogle Scholar
  • 12 Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel group randomized study.  J Neurol. 2006;  253 601-607
    CrossrefPubMedGoogle Scholar
  • 13 Reichmann H, Brecht M H, Koster J et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.  CNS Drugs. 2003;  17 965-973
    CrossrefPubMedGoogle Scholar
  • 14 Pahwa R, Stacy M A, Factor S A EASE-PD adjunct study investigators et al, on behalf of the . Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.  Neurology. 2007;  68 1108-1115
    CrossrefPubMedGoogle Scholar
  • 15 Naidu Y, Logishetty K, Martin A et al. Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease.  Park Rel Disord. 2009;  15 (S 02) S130 (P2.149)
    PubMedGoogle Scholar
  • 16 Kulisevsky J, Pascual-Sedano B, Barbanoj M et al. Acute effects of immediate and controlled release levodopa on mood in Parkinson's disease: a double blind study.  Mov Disord. 2006;  22 62-67
    PubMedGoogle Scholar
  • 17 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.  Lancet Neurol. 2008;  7 605-614
    CrossrefPubMedGoogle Scholar
  • 18 Hagell P, Odin P, Shing M. Apomorphin bei Morbus Parkinson.. Bremen: Uni-Med Verlag; 2005
    Google Scholar
  • 19 Colzi A, Turner K, Lees A J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1998;  64 573-576
    CrossrefPubMedGoogle Scholar
  • 20 Richard I H, Schiffer R B, Kurlan R. Anxiety and Parkinson's disease.  J Neuropsychiatry Clin Neurosci. 1996;  8 383-392
    PubMedGoogle Scholar
  • 21 Pluck G C, Brown R G. Apathy in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 2002;  73 636-642
    CrossrefPubMedGoogle Scholar
  • 22 Czernecki V, Schupbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson's disease: a dopamine responsive syndrome.  Mov Disord. 2008;  23 964-969
    CrossrefPubMedGoogle Scholar
  • 23 Marin R S, Fogel B S, Hawkin J et al. Apathy: a treatable syndrome.  J Neuropsychiatry Clin Neurosci. 1995;  7 23-30
    PubMedGoogle Scholar
  • 24 Goetz C G, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.  Ann Neurol. 2008;  64 (S 02) S81-92
    CrossrefPubMedGoogle Scholar
  • 25 Cools R, Stefanova E, Barker R et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.  Brain. 2002;  125 584-594
    CrossrefPubMedGoogle Scholar
  • 26 Mattay V, Tessitore A, Callicott J et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease.  Ann Neurol. 2002;  51 156-164
    CrossrefPubMedGoogle Scholar
  • 27 O'Sullivan S S, Evans A H, Lees A J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.  CNS Drugs. 2009;  23 157-170
    CrossrefPubMedGoogle Scholar
  • 28 Lees A J, Blackburn N A, Campbell V L. The nighttime problems of Parkinson's disease.  Clin Neuropharmacol. 1988;  11 512-519
    CrossrefPubMedGoogle Scholar
  • 29 Askenazy J J. Sleep disturbances in Parkinsonism.  J Neural Transm. 2003;  110 125-150
    CrossrefPubMedGoogle Scholar
  • 30 Dhawan V, Healy D G, Pal S et al. Sleep-related problems of Parkinson's disease.  Age Ageing. 2006;  35 220-228
    CrossrefPubMedGoogle Scholar
  • 31 Stocchi F, Vacca L, Valente M et al. Sleep disorders in Parkinson's disease.  Adv Neurol. 2001;  86 289-293
    PubMedGoogle Scholar
  • 32 Diederich N, Comella C. Sleep disturbances in Parkinson's disease.. In: Chokroverty S, Hening W A, Walters A, eds Sleep and Movement Disorders.. Philadelphia: Butterworth, Heinemann; 2003: 478-488
    Google Scholar
  • 33 Trenkwalder C, Boesch S, Ceballos-Baumann A et al. Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement.  Nervenarzt. 2008;  79 475-479
    CrossrefPubMedGoogle Scholar
  • 34 Garcia Ruiz P J. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.  Mov Disord. 2006;  21 727-728
    CrossrefPubMedGoogle Scholar
  • 35 Ng K Y, Chase T N, Colburn R W et al. Dopamine stimulation induced release from central neurons.  Science. 1971;  1172 487-489
    PubMedGoogle Scholar
  • 36 Rye D B, Jankovic J. Emerging views of dopamine in modulating sleep / wake state from an unlikely source: PD.  Neurology. 2002;  58 341-346
    PubMedGoogle Scholar
  • 37 Uchiyama T, Sakakibara R, Hattori T et al. Short-term eff ect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.  Mov Disord. 2003;  18 573-578
    CrossrefPubMedGoogle Scholar
  • 38 Christmas T, Kempster P, Chapple C et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.  Lancet. 1988;  2 1451-1453
    PubMedGoogle Scholar
  • 39 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson's disease and Related Disorders. Park Related Disorders P0II: 161.. Dresden; October/2008
    Google Scholar
  • 40 O'Sullivan J D, Hughes A J. Apomorphine induced penile erections in Parkinson's disease.  Mov Disord. 1998;  13 536-539
    CrossrefPubMedGoogle Scholar
  • 41 Dula E, Bukofzer S, Perdok R et al. Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.  Eur Urol. 2001;  39 558-564
    CrossrefPubMedGoogle Scholar
  • 42 Klos K J, Bower J H, Josephs K A et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.  Park Relat Disord. 2005;  11 381-386
    CrossrefPubMedGoogle Scholar
  • 43 Edwards L L, Quigley E MM, Harned R K et al. Defecatory function in Parkinson's disease: response to apomorphine.  Ann Neurol. 1992;  33 490-493
    PubMedGoogle Scholar
  • 44 Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life.  Mov Disord. 2009;  24 1468-1474
    CrossrefPubMedGoogle Scholar
  • 45 Brefel-Courbon C, Payoux P, Thalamas C et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.  Mov Disord. 2005;  20 1557-1563
    CrossrefPubMedGoogle Scholar
  • 46 Witjas T, Kaphan E, Azulay J P et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling.  Neurology. 2002;  59 408-413
    PubMedGoogle Scholar
  • 47 Ray Chaudhuri K, Abbott R J, Millac P AH. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.  J Neurol Neurosurg Psychiatry. 1990;  54 372-373
    PubMedGoogle Scholar
  • 48 Ellis C M et al. Use of apomorphine therapy in parkinsonian patients with neuropsychiatric complications to oral therapy.  Parkinsonism and Related Disorders. 1997;  3 103-107
    CrossrefPubMedGoogle Scholar
  • 49 van Laar T, Postma A G, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.  Park Relat Disord. 2010;  16 71-72
    CrossrefPubMedGoogle Scholar
  • 50 Martinez-Martin P, Todorova A, Henriksen T et al. The motor and non motor efficacy of subcutaneous apomrophine infusion in chronic advanced PD compared to Parkinson's patients on conventional therapy. A „real life” study.  Mov Disord 2010. Abstract In Press. To be Presented to Movement Disorders Congress. Buenos Aires; June 2010
    Google Scholar

Prof. Dr. med. Per Odin

Abt. Neurologie, Klinikum-Bremerhaven

Postbrookstr. 103

27574 Bremerhaven

Email: Per.odin@klinikum-bremerhaven.de

      >